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Pulling the puzzles apart 
Questions of science 
Science and progress  
 
Nobody said it was easy 
No one ever said it would be so hard 
 



































































































































































































































































































































































































































Altered immune response 
Auto-antibody production 
Tissue damage 
Cumulative structural damage 































































































Positive selection of self-
restricted T cells
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• Regulatory T cells
• Tissue modulation
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Table 2. Frequently used therapeutics in RA 
Conventional DMARDs                                                                  Mechanism of action
Methotrexate Folate antagonist, inhibits cell proliferation, cytokine 
production 
Leflunomide Dihydroorotate dehydrogenase inhibitor, inhibits pyrimidine synthesis, NFkB activation,TNFa and 
matrix metalloproteinases production
Hydroxychloroquine Inhibits B- and T cells activity and cytokine release
Sulfasalazine Folate antagonist, inhibits acachidonic acid cascade
Tofacitinib JAK1/2/3 inhibitor, inhibits cytokine production 
Biological DMARDs
Adalimumab- Human monoclonal antibody TNF inhibitor
Certolizumab pegol- F(ab’) fragment of a humanised monoclonal 
antibody TNF inhibitor
Etanercept- IgG–Fc-receptor construct (fusion protein) TNF inhibitor
Golimumab- Human monoclonal antibody TNF inhibitor
Infliximab- Chimeric monoclonal antibody TNF inhibitor
Rituximab- Chimeric monoclonal antibody against CD20 B- cell depletion
Abatacept- IgG–Fc-receptor construct (fusion protein)-CTLA4 Anti-T-cell co-stimulation
Tocilizumab IL-6 inhibitor
Corticosteroids 
prednisolone Inhibits acachidonic acid cascade













































































































































































Generation 1 (50% donor) 
Generation 2 (25% donor) 
Generation 3 (12.5% donor) 
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